SCHEMBL26112205

SCHEMBL26112205

O=C(O)Nc1nc2cc(Sc3ccc(N4CCC5(CC4)OCCO5)cc3)ccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
LMNA P02545 3/20 0.40
MEN1 O00255 3/20 0.40
NR1I2 O75469 1/20 0.40
CYP1A2 P05177 1/20 0.40
MAPK14 Q16539 1/20 0.40
ALDH1A1 P00352 8/20 0.37
GAA P10253 3/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PTPN11 Q06124 1/20 0.35
F12 P00748 1/20 0.35
HSD17B10 Q99714 3/20 0.35
GLA P06280 2/20 0.35
LGMN Q99538 1/20 0.35
KDM4E B2RXH2 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30590551 0.90 LMNA (0.52) KMT2ALMNAMEN1NR1I2CYP1A2
SCHEMBL26422318 0.90 LMNA (0.52) KMT2ALMNAMEN1NR1I2CYP1A2
SCHEMBL25370002 0.88 MEN1 (0.44) KMT2ALMNAMEN1NR1I2CYP1A2
SCHEMBL25368425 0.86 CYP1A2 (0.46) KMT2ALMNAMEN1NR1I2CYP1A2
SCHEMBL26110925 0.83 MEN1 (0.44) KMT2ALMNAMEN1NR1I2CYP1A2
SCHEMBL26111717 0.83 LMNA (0.43) KMT2ALMNAMEN1NR1I2CYP1A2
SCHEMBL26131369 0.83 LMNA (0.46) KMT2ALMNAMEN1NR1I2CYP1A2
SCHEMBL26114020 0.82 CYP1A2 (0.43) KMT2ALMNAMEN1NR1I2CYP1A2
Hydrochloric Acid SCHEMBL26128281 0.82 LMNA (0.45) KMT2ALMNAMEN1NR1I2CYP1A2
SCHEMBL26111068 0.82 LMNA (0.43) KMT2ALMNAMEN1NR1I2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214987-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-07-03 US disclosed
US-20250214945-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-07-03 US disclosed
EP-4506346-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF Korea University Research and Business Foundation (KR) 2025-02-12 EP disclosed
EP-4501915-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR Korea University Research and Business Foundation (KR) 2025-02-05 EP disclosed
WO-2023191536-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF 고려대학교 산학협력단 2023-10-05 WO disclosed
WO-2023191533-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR 고려대학교 산학협력단 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214987-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR WEE1, WEE2, HADHB KMT2A 1621/4885LMNA 4720/4885MEN1 2194/4885
US-20250214945-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF TTBK2, TUBB3, TUBB KMT2A 1387/4885LMNA 4174/4885MEN1 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.